The objective of the Glioma SPORE Developmental Research Program (DRP) is to identify innovative pilot research projects in glioblastoma that have translational potential. The DRP will establish a solicitation and review process to select meritorious pilot projects for funding. The solicitation process will capitalize on an established, extensive Dana-Farber/Harvard Cancer Center (DF/HCC) communications Infrastructure to widely disseminate an annual Request for Proposals (RFP). The review process will utilize an experienced panel of DF/HCC glioma scientists. The DRP will provide limited-duration funding for innovative projects that have ultimate translational potential and could synergize with existing SPORE projects and cores. The DRP applications will also be judged for their potential to emerge as full projects in future years of the SPORE program. The DRP will employ a monitoring process to measure progress and outcomes of DRP projects including the possible elevation of successful DRP awards to full projects. The program will be closely monitored through clearly established metrics and oversight by the DRP Awards Committee. DRP awardees will be required to present progress reports at the annual SPORE retreat attended by the SPORE Internal and External Advisory Boards.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA165962-03
Application #
8936618
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Program Officer
Arnold, Julia T
Project Start
Project End
2016-07-31
Budget Start
2015-08-01
Budget End
2016-07-31
Support Year
3
Fiscal Year
2015
Total Cost
$307,707
Indirect Cost
$75,223
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02114
Zhao, Yingchao; Liu, Pinan; Zhang, Na et al. (2018) Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models. Proc Natl Acad Sci U S A 115:E2077-E2084
Bian, X; Gao, J; Luo, F et al. (2018) PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. Oncogene 37:341-351
McBrayer, Samuel K; Mayers, Jared R; DiNatale, Gabriel J et al. (2018) Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. Cell 175:101-116.e25
McKenney, Anna Sophia; Lau, Allison N; Somasundara, Amritha Varshini Hanasoge et al. (2018) JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition. J Clin Invest 128:789-804
Shankar, Ganesh M; Kirtane, Ameya R; Miller, Julie J et al. (2018) Genotype-targeted local therapy of glioma. Proc Natl Acad Sci U S A 115:E8388-E8394
Arvanitis, Costas D; Askoxylakis, Vasileios; Guo, Yutong et al. (2018) Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood-tumor barrier disruption. Proc Natl Acad Sci U S A 115:E8717-E8726
Li, Ben B; Qian, Changli; Roberts, Thomas M et al. (2018) Targeted Profiling of RNA Translation. Curr Protoc Mol Biol :e71
Nowosielski, Martha; Wen, Patrick Y (2018) Imaging Criteria in Neuro-oncology. Semin Neurol 38:24-31
Li, Ben B; Qian, Changli; Gameiro, Paulo A et al. (2018) Targeted profiling of RNA translation reveals mTOR-4EBP1/2-independent translation regulation of mRNAs encoding ribosomal proteins. Proc Natl Acad Sci U S A 115:E9325-E9332
Khandekar, Melin J; Jain, Rakesh (2018) Smooth sailing for immunotherapy for unresectable stage III non-small cell lung cancer: the PACIFIC study. Transl Cancer Res 7:S16-S20

Showing the most recent 10 out of 84 publications